SVC Assessment for POTS

This trial aims to understand why individuals with postural tachycardia syndrome (POTS) feel worse after consuming high-carbohydrate foods. Researchers seek to determine if increased blood pooling in the stomach area post-meal is linked to these symptoms. Participants will receive glucose (a type of sugar) to observe its effects on blood flow and heart rate while lying down and standing up. The trial seeks individuals diagnosed with POTS who experience dizziness or lightheadedness after meals. The study will measure splanchnic venous capacitance (SVC) to assess changes in blood flow. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant findings.

The trial does not specify if you need to stop taking your current medications, but it excludes those on chronic medications and certain specific drugs like acetaminophen and statins. It's best to discuss your current medications with the trial coordinators.

Research has shown that the treatment GIP(3-30)NH2 works better at certain doses. In earlier studies, participants generally tolerated GIP(3-30)NH2 well, with no major reports of serious side effects. This suggests the treatment is usually safe for people. However, participants should discuss possible risks with their doctors before joining a trial.¹²³⁴⁵

Researchers are excited about this trial because it aims to uncover how the body's blood vessels respond to changes in blood flow and pressure, specifically in people with Postural Tachycardia Syndrome (POTS). Unlike standard treatments that focus on managing symptoms like rapid heart rate, this study is investigating the role of splanchnic venous capacitance (SVC) and glucose-dependent insulinotropic polypeptide (GIP) hormones. The trial could pave the way for new therapies targeting the blood flow dynamics in POTS, offering a fresh perspective on managing this challenging condition. By exploring these unique physiological mechanisms, the trial could lead to breakthroughs in understanding and treating POTS beyond current symptomatic relief options.

In this trial, one arm will assess the effect of the treatment GIP(3-30)NH2 on people with POTS by blocking a gut hormone that can worsen symptoms. Research has shown that GIP(3-30)NH2 may reduce the effects of this hormone, potentially preventing blood from pooling and improving blood flow after eating. This treatment targets blood volume in the stomach area and may help maintain steady blood pressure and heart rate when standing. Early results suggest that GIP(3-30)NH2 could reduce the dizziness and lightheadedness often experienced in POTS after meals.¹²³⁴⁵